Valuation : Alkermes plc

Market Cap 7.71B 6.64B 6.29B 5.7B 10.7B 737B 10.75B 74.73B 28.74B 375B 28.96B 28.33B 1,184B P/E 2026 *
-90.1x
P/E 2027 * 63.3x
Enterprise Value 8.46B 7.29B 6.9B 6.25B 11.73B 808B 11.79B 81.93B 31.51B 411B 31.76B 31.06B 1,299B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.31x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.30%
1 week-0.28%
Current month-2.17%
1 month-8.57%
3 months+3.82%
6 months+66.32%
Current year+64.30%
1 week 44.63
Extreme 44.63
46.75
1 month 44.63
Extreme 44.63
51.29
Current year 27
Extreme 27
55.67
1 year 26.4
Extreme 26.4
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Sell

Compliance Officer

-2,034 0.0012%
1/9/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/8/26 Sell

Executive/Senior Manager

-7,576 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-0.28%+70.45%+50.08% 7.71B
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average +0.41%-3.24%+63.71%+98.86% 27.25B
Weighted average by Cap. +0.39%-3.57%+74.44%+122.02%

Financials

2026 *2027 *
Net sales 1.82B 1.57B 1.49B 1.35B 2.53B 174B 2.54B 17.68B 6.8B 88.7B 6.85B 6.7B 280B 1.94B 1.68B 1.59B 1.44B 2.7B 186B 2.71B 18.84B 7.25B 94.53B 7.3B 7.14B 299B
Net income -89.92M -77.47M -73.36M -66.49M -125M -8.59B -125M -871M -335M -4.37B -338M -330M -13.81B 120M 104M 98.13M 88.95M 167M 11.49B 168M 1.17B 448M 5.85B 452M 442M 18.47B
Net Debt 744M 641M 607M 550M 1.03B 71.07B 1.04B 7.21B 2.77B 36.16B 2.79B 2.73B 114B 670M 577M 547M 495M 929M 64B 934M 6.49B 2.5B 32.56B 2.52B 2.46B 103B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
11/09/26 USD 45.97 -0.30% 1,283,128
10/09/26 USD 46.11 +1.56% 1,193,903
09/09/26 USD 45.40 -0.20% 1,442,769
08/09/26 USD 45.49 -1.32% 1,355,832
04/09/26 USD 46.10 -1.66% 1,064,034
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
45.97USD
Average target price
56.00USD
Spread / Average Target
+21.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!